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SORT IT SUPPLEMENT: POST-EBOLA RECOVERY IN WEST AFRICA
Influence of Ebola on tuberculosis case finding and treatment 
outcomes in Liberia
P. K. Konwloh,1 C. L. Cambell,1 S. Ade,2,3,4 P. Bhat,5 A. D Harries,2,6 E. Wilkinson,7 C. T. Cooper1
Despite the progress made globally in the last 20 years with the implementation of the World Health 
Organization’s (WHO’s) Stop TB strategy, tuberculosis 
(TB) remains a major public health threat. It is estimated 
that one third of the world’s population is infected with 
Mycobacterium tuberculosis, and 5–10% of infected per-
sons are at risk of developing active TB during their life-
time. In 2014, an estimated 9.6 million people world-
wide developed new active TB and 1.5 million people 
died from the disease, of whom 390 000 had associated 
human immunodeficiency virus (HIV) infection.1
Liberia is among several countries in West Africa 
where TB is a significant public health problem. The 
National Leprosy and Tuberculosis Control Pro-
gramme (NLTCP) has been implementing DOTS-based 
TB control activities for many years in Liberia in line 
with WHO recommendations.2 Between 2011 and 
2013, the numbers of notified cases of new and re-
lapse TB ranged from 7500 to 8000 per annum, with 
an estimated case detection rate of 55–60% and a 
treatment success rate in new TB cases of around 
80%.3
In 2013, West Africa was hit by Ebola virus disease 
(EVD), a severe, often fatal, zoonotic filovirus infec-
tion;4 the outbreak started in Guinea in December 
2013 and rapidly spread to Sierra Leone and Liberia.5,6 
Liberia diagnosed its first cases of Ebola in late March 
2014, with the peak of the outbreak occurring be-
tween August and October 2014. The WHO declared 
Liberia free of Ebola on 9 May 2015. However, the 
country experienced another cluster of six cases in 
June 2015, was declared free of transmission on 3 Sep-
tember, experienced three more cases in November 
and was again declared Ebola-free on 14 January 
2016.6 By June 2016, Liberia had reported 10 678 
cases, with 4810 associated deaths.6
In all three affected countries in the region, disrup-
tions occurred in the national programmes for TB, 
HIV/AIDS (acquired immune-deficiency syndrome) 
and malaria.7 Programme officers became sick, of 
whom some died as a result of Ebola. Many clinical 
teams and facilities were repurposed as part of the Eb-
ola response, which took staff away from their disease 
control activities. With the ‘no touch’ policy in place, 
problems were reported with the delivery of anti-tu-
berculosis treatment and reduced uptake of HIV test-
ing, which is performed with fingerpricks using rapid 
dipstick technology.8 In Guinea, the Ebola outbreak 
was reported to have resulted in an overall decline in 
the reporting of new TB cases,9 although another 
study in the same country showed that in facilities 
supported by non-governmental organisations, and 
where contingency planning was implemented, TB 
case finding and TB services could be maintained at 
satisfactory levels.10
These conflicting reports make it important to fur-
ther assess what happened to TB case finding and 
treatment outcomes as a result of the EVD outbreak, 
and whether there were any particular types or cate-
gory of TB or TB-HIV interventions that were particu-
larly affected and which subsequently recovered in the 
post-Ebola period. This information may be useful at 
programme level to maintain services if another Ebola 
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Setting: National Leprosy and Tuberculosis (TB) Control 
Programme, Liberia.
Objectives: To assess TB case finding, including human 
immunodeficiency virus (HIV) associated interventions 
and treatment outcomes, before (January 2013–March 
2014), during (April 2014–June 2015) and after (July–De-
cember 2015) the Ebola virus disease outbreak.
Design: A cross-sectional study and retrospective cohort 
analysis of outcomes.
Results: The mean quarterly numbers of individuals with 
presumptive TB and the proportion diagnosed as 
smear-positive were: pre-Ebola (n = 7032, 12%), Ebola (n 
= 6147, 10%) and post-Ebola (n = 6795, 8%). For all 
forms of TB, stratified by category and age group, there 
was a non-significant decrease in the number of cases 
from the pre-Ebola to the Ebola and post-Ebola periods. 
There were significant decreases in numbers of cases with 
smear-positive pulmonary TB (PTB) from the pre-Ebola 
period (n = 855), to the Ebola (n = 640, P < 0.001) and 
post-Ebola (n = 568, P < 0.001) periods. The proportions 
of patients tested for HIV, found to be HIV-positive and 
started on antiretroviral therapy decreased as follows: 
pre-Ebola (respectively 72%, 15% and 34%), Ebola 
(69%, 14% and 30%) and post-Ebola (68%, 12% and 
26%). Treatment success rates among TB patients were: 
80% pre-Ebola, 69% Ebola (P < 0.001) and 73% post-Eb-
ola (P < 0.001). Loss to follow-up was the main contribut-
ing adverse outcome.
Conclusion: The principal negative effects of Ebola were 
the significant decreases in diagnoses of smear-positive 
PTB, the declines in HIV testing and antiretroviral therapy 
uptake and poor treatment success. Ways to prevent 
these adverse effects from recurring in the event of an-
other Ebola outbreak need to be found.
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outbreak occurs in the future. We therefore undertook 
an assessment of TB case finding and treatment out-
comes to observe what happened to patients before, 
during and after the Ebola outbreak in Liberia at the 
national level.
METHODS
Study design
This was a cross-sectional study combined with a retro-
spective cohort study of new smear-positive pulmo-
nary TB (PTB) patients and their treatment outcomes 
using NLTCP data.
Setting
General setting
Liberia, situated in West Africa, is bordered by Guinea, 
Sierra Leone, Ivory Coast and the Atlantic Ocean. The 
estimated population is approximately 4 million, of 
whom approximately half live in urban areas. The per 
capita gross national income is US$2012.11 The coun-
try is divided administratively into 15 counties, which 
include 91 health districts. Medical services are pro-
vided by a mixture of public, private and non-govern-
mental organisations (NGOs). In the public sector, 
health services are free of charge, including those for 
TB and HIV/AIDS.
TB control services in Liberia
Liberia started using the DOTS strategy for TB in 1999, 
and coverage at the county level is 100%.12 The NLTCP 
is responsible for all TB control activities, including 
the country’s two specialised TB hospitals and 161 TB 
diagnostic/treatment centres distributed among the 
727 health facilities in Liberia. Most TB diagnosis and 
treatment is conducted in the public sector, but some 
private, faith- and industry-based facilities undertake 
these activities free of charge based on a memorandum 
of understanding between the government and the 
private sector.
Clinicians and nurses provide routine diagnostics, 
management and care for patients with presumptive 
and diagnosed TB in the health facilities in line with 
WHO recommendations.2 Patients are identified as hav-
ing presumptive TB if they have cough of 2 weeks, 
and are investigated at TB diagnostic/treatment centres 
by sputum smear microscopy and chest radiography 
with set criteria used to diagnose smear-positive PTB, 
smear-negative PTB and PTB with smear not performed. 
Extra-pulmonary TB (EPTB) is diagnosed on the basis of 
clinical, radiographic and other supportive evidence. 
Diagnosed patients are registered according to the type 
of TB, and treatment is based on the category of TB 
(new or previously treated) using internationally recom-
mended standardised treatment regimens of 6 months 
for new patients or 8 months for previously treated pa-
tients (provided there is no evidence of multidrug resis-
tance), in line with WHO recommendations.2,13 All TB 
patients are offered HIV testing; those found to be 
HIV-positive are started on cotrimoxazole preventive 
therapy (CPT) and antiretroviral therapy (ART).
All patients are monitored until the end of treat-
ment and are then assessed in relation to their treat-
ment outcomes based on standardised WHO criteria, 
with the results recorded on the patient treatment 
cards and in the TB patient registers.2 Data at clinic 
level are collected daily and quarterly by clinicians 
and/or nurses, with supervision to check data accuracy 
undertaken monthly at the county level and quarterly 
by the central unit. The checked data are then sent to 
the district health office, transferred up the system to 
the county level, and from there to the Ministry of 
Health (MoH) through the Health Management Infor-
mation System (HMIS). The data are collated as quar-
terly aggregate numbers in the HMIS.
Study population
The study included all patients in Liberia with pre-
sumptive and active TB who were investigated, diag-
nosed, registered or treated between 2013 and 2015 in 
the pre-Ebola (1 January 2013–31 March 2014), Ebola 
(1 April 2014–30 June 2015) and post-Ebola (1 July–31 
December 2015) periods. Treatment outcomes were re-
ported for new smear-positive PTB patients during the 
time periods studied for those enrolled in treatment up 
to 1 year previously.
Data variables, sources of data and data 
collection
The key data variables included, on a quarterly basis: 
year; quarter; number of presumptive TB patients in-
vestigated; patients with a positive sputum smear re-
sult; types and categories of TB stratified by age (0–4, 
5–14 and ≥15 years); HIV testing and, of those found 
to be HIV-positive, the numbers started on CPT and 
ART; and the treatment outcomes of patients with 
new and relapse smear-positive TB. The primary 
source of data was the HMIS at the MoH 
headquarters.
Analysis and statistics
Data were extracted from the District Health Informa-
tion System version 2 (Oslo, Norway) into an Excel 
database (Microsoft Corp, Redmond, WA, USA). A de-
scriptive analysis was performed for the case finding, 
HIV testing and treatment outcomes in the pre-Ebola 
(1 January 2013–31 March 2014), Ebola (1 April 2014–
30 June 2015) and post-Ebola (1 July–31 December 
2015) periods. Quarterly means and standard errors 
were calculated for absolute numbers, and average 
proportions were derived during the pre-Ebola, Ebola 
and post-Ebola periods. Comparisons were made be-
tween the pre-Ebola and Ebola periods and between 
the pre-Ebola and post-Ebola periods. The quarterly 
means and standard errors were compared using Stu-
dent’s t-test, and proportions were compared using 
the χ2 test. Levels of significance were set at 5% (P < 
0.05).
Ethics
Approval for the study was obtained from the Pacific 
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RESULTS
Presumptive tuberculosis
The numbers of persons with presumptive TB registered at labora-
tories and the proportions smear-positive are shown in Table 1 
and Figure 1. Presumptive TB declined in the Ebola period, partic-
ularly at the peak of the outbreak in the third quarter of 2014, 
and then increased in the post-Ebola period, although these 
changes were not significant. The proportion of persons found to 
be smear-positive declined significantly in the Ebola period and 
decreased again in the post-Ebola period.
Tuberculosis cases
The numbers of patients registered with TB, stratified by type, cat-
egory and age group, are shown in Table 1, Figure 2 and Figure 3. 
For TB all forms, stratified by category and age group, there was a 
non-significant decrease in numbers from the pre-Ebola period to 
the Ebola and post-Ebola periods. The most marked decreases in 
TB cases were in the last two quarters of 2014 during the peak of 
the outbreak. The key finding was a significant decrease in 
smear-positive PTB in the Ebola and post-Ebola periods, and a sig-
nificant decrease in EPTB in the Ebola period.
HIV testing and care
Information on HIV testing results, positive diagnoses and care 
are shown in Table 1 and Figure 4. From the pre-Ebola period to 
the Ebola and post-Ebola periods, there were progressive decreases 
in the proportion of TB patients tested for HIV, found to be 
HIV-positive and started on CPT and ART, and these were espe-
cially marked in the last two quarters of 2014. Significant de-
creases were seen in HIV testing, the number of HIV-positive re-
sults and the uptake of ART in the post-Ebola period compared 
with the pre-Ebola period.
Treatment outcomes
The treatment success rates in new smear-positive PTB patients 
enrolled 1 year previously are shown in Table 2 and Figure 5. 
Treatment success was significantly lower among the patients re-
ported in the Ebola and post-Ebola periods, although it improved 
slightly post-Ebola. The key contributing adverse outcomes that 
significantly increased in these two periods were loss to follow-up, 
transfer-out and failure.
TABLE 1 National cases of presumptive and registered TB along 
with HIV testing and care in the pre-Ebola, Ebola and post-Ebola 
disease outbreak periods,* Liberia, 2013–2015
Characteristics
Quarterly means and/or percentages†
Pre-Ebola
n
Ebola
n
Post-Ebola
n
Presumptive TB
 Presumptive TB cases 
investigated
7032 6147 6795
 Identified as smear-
positive, %
12 10‡ 8‡
Registered TB
 All forms 1754 1467 1373
 New smear-positive PTB 855 640§ 568§
 New smear-negative 
PTB/smear not 
performed
409 427 406
 New EPTB 460 372§ 395
 All new TB 1724 1439 1369
 All previously treated TB 30 28 4§
 Children aged 0–14 years 
with new TB
226 186 199
 Adults aged ≥ 15 years 
with new TB
1498 1253 1170
HIV testing and care, %
 TB patients tested for HIV 72 69 68§
 HIV-positive 15 14 12§
 HIV-positive patients 
given CPT
74 71 71
 HIV-positive patients 
given ART
34 30 26§
* Pre-Ebola period = 1 January 2013–31 March 2014; Ebola period = 1 April 2014–30 
June 2015; post-Ebola period = 1 July–31 December 2015.
† Comparisons were made between 1) the pre-Ebola and the Ebola period, and 2) 
between the pre-Ebola and the post-Ebola period. Quarterly means and standard er-
rors (not shown) were compared using Student’s t-test. Proportions were compared 
with the χ2 test.
‡ P < 0.001.
§ P < 0.05.
TB = tuberculosis; HIV = human immunodeficiency virus; PBT = pulmonary tubercu-
losis; EPTB = extra-pulmonary tuberculosis; CPT = cotrimoxazole preventive therapy; 
ART = antiretroviral therapy.
FIGURE 1 Numbers of persons with presumptive TB investigated nationally per 
quarter along with those identified as sputum smear-positive before, during and af-
ter the Ebola outbreak in Liberia, 2013–2015. Pre-Ebola period = 1 January 2013–31 
March 2014; Ebola period = 1 April 2014–30 June 2015; post-Ebola period = 1 July–
31 December 2015. TB = tuberculosis.
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DISCUSSION
This is the first study to report on the effects of the EVD outbreak 
on TB case finding and treatment outcomes in Liberia. There were 
some important findings. First, there was a striking decline in the 
detection of presumptive smear-positive TB and in patients regis-
tered with smear-positive PTB in the Ebola period, and this con-
tinued into the post-Ebola period. Second, there were progressive 
decreases in HIV testing, HIV-positive test results and uptake of 
ART from the pre-Ebola to the Ebola and post-Ebola periods, 
reaching statistical significance in the post-Ebola period. Third, 
treatment success rates decreased, although this did improve 
somewhat in the post-Ebola period. The main contributory ad-
verse outcomes were loss to follow-up, transfer-out and failure. Fi-
nally, the most marked declines in case finding, HIV testing and 
treatment outcomes occurred in the last two quarters of 2014, 
when the Ebola outbreak was at its peak.
The strengths of this study were the use of the national data-
base, for which the data are checked at facility and county level, 
and the conduct and reporting of the study in line with the 
STrengthening the Reporting of OBservational studies in Epidemi-
ology (STROBE) guidelines and sound ethics principles.14,15 The 
study’s limitations are related to the usual problems of accuracy 
and completeness of routinely collected data, particularly as data 
quality during the Ebola and post-Ebola periods may have de-
clined due to a lack of supportive supervision. There is also no in-
formation about the timing of CPT or ART initiation in TB pa-
tients infected with HIV, both of which are important for 
treatment success and survival.16,17
The overall decreases in the numbers of patients presenting 
with presumptive TB, which in turn led to decreases in the num-
bers diagnosed and registered with TB, may have been due to 
symptomatic patients with cough and fever avoiding health facil-
ities due to fears of contracting or being diagnosed with Ebola or 
because of imposed quarantine measures.18 Decreases in the num-
bers of cases with TB may also have been due to EVD increasing 
mortality in this patient group at the time that patients devel-
oped symptoms. The significant declines in diagnoses of 
smear-positive TB may have been due to health-care workers, in-
cluding laboratory technicians, becoming ill or dying from Ebola, 
being redeployed in the community to help manage presumed 
and confirmed Ebola cases, and difficulties in performing labora-
tory procedures due to the ‘no touch’ policy. This policy may also 
have been one of the reasons for the significant decline in EPTB, 
for which clinical assessment and investigative procedures are 
crucial for diagnosis. As testing for HIV with rapid diagnostic test 
kits requires fingerprick testing, which is generally discouraged 
during an Ebola outbreak,8 it is not surprising to see a decline in 
HIV testing rates. In the post-Ebola period, however, the propor-
tions of patients diagnosed with smear-positive TB and undergo-
ing testing for HIV continued to decrease. The reasons for this are 
incompletely understood, but include delays in the procurement 
and distribution of consumables, delays in the training and re-
placing of essential staff and a lack of supervision, which is essen-
tial for maintaining standards.19
Treatment success rates deteriorated during the Ebola outbreak 
and did not return to the pre-Ebola levels. This was due mainly to 
high losses to follow-up, which increased from 10% to nearly 
20% during the Ebola outbreak. Loss to follow-up can include un-
reported deaths,20 which may have been a factor among regis-
tered TB patients in Liberia. Interestingly, treatment failure rates 
increased. This may be due to patients interrupting treatment due 
to the various reasons discussed earlier, and is of concern, as fail-
ure may lead to drug-resistant TB.21
It is clear that the Ebola outbreak in Liberia had serious nega-
tive effects on many aspects of the NLTCP, which had still not 
fully recovered in the 6-month post-Ebola period. What can be 
done to hasten the recovery and prepare for future outbreaks? 
Laboratory capacity needs to be strengthened and consideration 
given to increased coverage of rapid point-of-care molecular diag-
nostic tests for TB, such as Xpert® MTB/RIF (Cepheid, Sunnyvale, 
CA, USA), which can eliminate some of the burdensome labora-
tory work involved with the preparation and reading of sputum 
smears.22 The NLTP needs to strengthen collaboration with the 
HIV/AIDS programme and identify alternative ways of perform-
ing HIV testing other than using fingerpricks, such as oral salivary 
testing,23 and ensuring uninterrupted supplies of HIV test kits and 
antiretroviral drugs. Despite the quarantine measures and travel 
FIGURE 2 Numbers of TB cases (all forms) registered nationally per quarter before, during 
and after the Ebola outbreak in Liberia, 2013–2015. Pre-Ebola period = 1 January 2013–31 
March 2014; Ebola period = 1 April 2014–30 June 2015; post-Ebola period = 1 July–31 De-
cember 2015. TB = tuberculosis.
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FIGURE 3 Numbers of TB cases registered nationally each quarter, stratified by type of TB, retreatment and 
age, before, during and after the Ebola outbreak in Liberia, 2013–2015. A) New TB cases, stratified by type of 
disease. B) Retreatment TB cases. C) All TB cases, stratified by children (aged 0–14 years) and adults (aged ≥ 15 
years). Pre-Ebola period = 1 January 2013–31 March 2014; Ebola period = 1 April 2014–30 June 2015; post-Eb-
ola period = 1 July–31 December 2015. TB = tuberculosis.
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FIGURE 4 HIV testing and HIV care for TB cases registered nationally per quarter before, during and after the 
Ebola outbreak in Liberia, 2013–2015. A) Numbers of TB cases tested for HIV. B) HIV-positive TB cases of those 
tested for HIV. C) HIV-positive TB patients placed on CPT and ART. Pre-Ebola period = 1 January 2013–31 
March 2014; Ebola period = 1 April 2014–30 June 2015; post-Ebola period = 1 July–31 December 2015. TB = 
tuberculosis; HIV = human immunodeficiency virus; CPT = cotrimoxazole preventive therapy; ART = antiretrovi-
ral therapy. 
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restrictions, ways need to be found to maintain key NLTCP activi-
ties such as providing personal protective measures against Ebola 
for key front-line staff, ensuring regular and timely distribution of 
anti-tuberculosis drugs and consumables to facilities and main-
taining facility-based supervision.19 Finally, guidance is needed 
from the WHO about when to start and when to stop emergency 
procedures, which would help programmes to be more resilient in 
the event of another Ebola outbreak.
In conclusion, this is the first national study from Liberia to 
assess the effect of the Ebola outbreak on TB control activities 
both during and after the outbreak. The principal negative effects 
were a significant decrease in the diagnosis of smear-positive PTB, 
a decline in HIV testing and ART uptake, and poor treatment suc-
cess, largely due to high losses to follow-up. Ways to hasten the 
recovery of and to mitigate these adverse effects on TB control in 
the case of a future outbreak are needed.
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tered nationally per quarter, before, during and after the Ebola outbreak in Li-
beria, 2012–2014. *Cured and treatment completed. Pre-Ebola period = 1 Jan-
uary 2013–31 March 2014; Ebola period = 1 April 2014–30 June 2015; 
post-Ebola period = 1 July–31 December 2015. PTB = pulmonary tuberculosis.
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Contexte  :  Programme national de la tuberculose (TB), Liberia.
Objectifs  :  Evaluer la détection des cas de TB, y compris les 
interventions associées au virus de l’immunodéficience humaine (VIH) 
et les résultats du traitement, avant (1 janvier 2013–31 mars 2014), 
pendant (1 avril 2014–30 juin 2015) et après la flambée d’Ebola (1 
juillet–31 décembre 2015).
Schéma  :  Une etude transversale et analyse de cohorte rétrospective 
des résultats.
Résultats  :  Le nombre moyen mensuel par trimestre de présomptions 
de TB et de pourcentages de frottis positifs détectés était : pré-Ebola 
(n = 7032, 12%), pendant Ebola (n = 6147, 10%) et post-Ebola (n = 
6795, 8%). Pour les TB toutes formes, stratifiées par catégorie et 
groupe d’âge, il y a eu une diminution non significative des nombres 
des périodes pré-Ebola à pendant Ebola et post-Ebola. Il y a eu une 
diminution significative des TB pulmonaire à frottis positif : pré-Ebola 
(855), pendant-Ebola (640, P < 0,001) et post-Ebola (568, P < 0,001). 
Les proportions de patients testés pour le VIH, trouvés VIH positifs et 
mis sous traitement antirétroviral (TAR) ont diminué : pré-Ebola 
(respectivement 72%, 15% et 34%), Ebola (69%, 14% et 30%) et 
post-Ebola (68%, 12% et 26%). Les taux de succès du traitement des 
patients TB ont été 80% pré-Ebola, 69% pendant Ebola (P < 0,001) 
et 73% post-Ebola (P < 0,001), avec les pertes de vue comme 
contributions principales aux résultats défavorables.
Conclusion  :  Les principaux effets négatifs d’Ebola ont été des 
diminutions significatives du diagnostic de TBP à frottis positif, des 
déclins du test VIH et de la prise du TAR et un résultat médiocre du 
traitement. Il faut trouver des moyens d’éviter que ces effets négatifs 
ne surviennent à nouveau en cas de nouvelle épidémie.
Marco de referencia: El programa nacional contra la tuberculosis 
(TB) de Liberia.
Objetivos: Evaluar la búsqueda de casos de TB teniendo en cuenta 
las intervenciones asociadas con el virus de la inmunodeficiencia 
humana (VIH) y examinar los desenlaces terapéuticos antes del brote 
epidémico de fiebre hemorrágica del Ébola (de 1 enero del 2013 a 31 
marzo del 2014), durante el brote (del 1 abril del 2014 a 30 junio del 
2015) y después del mismo (de 1 julio a 31 diciembre del 2015).
Método: Un estudio transversal con análisis de cohortes 
retrospectivo de los desenlaces terapéuticos.
Resultados: Antes de la epidemia, el promedio mensual por 
trimestres de los casos con presunción de TB fue 7032 (12% de 
baciloscopias positivas), durante el brote fue 6147 (10%) y después 
de la epidemia fue 6795 (8%). En todos los casos de TB, estratificados 
por categorías y grupos de edad, durante la epidemia y después de 
ella se observó una disminución no significativa de las cifras, en 
comparación con el período anterior a la epidemia. Ocurrió una neta 
disminución de los casos de TB pulmonar con baciloscopia positiva, a 
saber: antes de la epidemia del Ébola n = 855, durante el brote n = 
640 (P < 0,001) y después del mismo n = 568 (P < 0,001). Se observó 
una disminución de la proporción de pacientes en quienes se practicó 
la prueba del VIH, que obtuvieron un resultado positivo y que 
iniciaron el tratamiento antirretrovírico (ART), respectivamente como 
sigue: antes del brote del Ébola 72%, 15% y 34%, durante la 
epidemia 69%, 14% y 30% y después del brote 68%, 12% y 26%. La 
tasa de éxito del tratamiento antituberculoso fue 80% antes del 
brote, 69% durante la epidemia (P < 0,001) y 7% después de la 
misma (P < 0,001); el desenlace desfavorable predominante fue la 
pérdida durante el seguimiento.
Conclusión: Las principales consecuencias negativas de la epidemia 
del Ébola fueron una disminución considerable en el diagnóstico de 
TB pulmonar con baciloscopia positiva, una reducción de la práctica 
de la prueba del VIH y de la iniciación del ART y tasas insuficientes de 
éxito terapéutico. Se recomienda definir las medidas que puedan 
evitar estas consecuencias adversas, en la eventualidad de una futura 
epidemia.
